/ /

  • linkedin
  • Increase Font
  • Sharebar

    Valeant acquires Nicox’s US ophthalmic diagnostics subsidiary

    Sophia Antipolis, France—Valeant Pharmaceuticals International has acquired Nicox S.A.’s U.S. diagnostics subsidiary, Nicox, Inc., in a deal worth up to $20 million.

    According to the company, Nicox intends to concentrate its commercial and development resources on ophthalmic therapeutics as part of its strategy to build an international ophthalmic company in Europe and in the United States.

    In case you missed it: pharmacological approach to dry eye syndrome in GVHD

    “The decision reflects the significant opportunities available to Nicox in light of the recent acquisition of Aciex and positive phase III results for Vesneo,” the company said in a prepared statement Monday.

    Under the terms of the transaction, Valeant has acquired most of the Nicox commercial infrastructure in the United States associated with diagnostics, while Nicox has retained a number of U.S.-based employees focused on therapeutics.

    Rose Schneider Krivich
    Rose is the content specialist for Medical Economics.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results